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another and with volume of local recurrence at progres-
sion quantitatively and qualitatively by calculating the con-
formity index (CI), the overlapping volume as a proportion 
of the total combined volume, where 1 = identical plans 
and 0 = no conformation whatsoever. Gross tumour vol-
umes (GTVs) using ADC and post-contrast T1-weighted 
sequences were quantitatively the same (related samples 
Wilcoxon signed rank test = −0.45, p = 0.653) but showed 
difering conformations (CI 0.53, p < 0.001). The difusion 
treatment volume (DTV) obtained by combining the two 
target volumes was signiicantly greater than the treatment 
volume based on post contrast T1-weighted MRI alone, 
both quantitatively (median 13.65 vs. 9.52  cm3, related 
samples Wilcoxon signed rank test p < 0.001) and quali-
tatively (CI 0.74, p = 0.001). This DTV covered a greater 
volume of subsequent tumour recurrence than the standard 
plan (median 3.53 cm3 vs. 3.84 cm3, p = 0.002). ADC maps 
may be a useful tool in addition to the standard post-con-
trast T1-weighted sequence used for SRS planning.
Keywords Brain metastasis · Stereotactic radiosurgery · 
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Introduction
Brain metastases are increasingly common and cause sig-
niicant morbidity and mortality in patients with solid 
tumours [1–4]. Recent analyses of the brain–brain metas-
tasis interface [5, 6] suggest local invasion may be more 
important than previously thought [7] and various solu-
tions including supra-marginal surgical resection and cavity 
boost stereotactic radiosurgery (SRS) have been proposed 
[8–10]. MRI scans of the brain are routinely obtained in 
the course of diagnosis and disease monitoring for these 
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patients and difusion MRI (DWI) sequences are commonly 
included, historically to distinguish these ring enhancing 
tumours from abscesses but more recently to aid in difer-
entiating solitary metastases from glioma, for surgical plan-
ning and even to predict prognosis [11]. It is known that 
in human brain metastases the apparent difusion coei-
cient (ADC) increases with decreasing cellularity [12] and 
decreasing density of intratumoral connective tissue [13]. 
Changes in ADC in the peritumoral brain may precede 
micro-metastasis appearance in animal models [14] and 
lower tumour ADC values have been shown to be predic-
tive of earlier recurrence and shorter survival after neuro-
surgery [12, 13] and SRS [15]. The aim of this study was to 
investigate whether the addition of an ADC map to a stand-
ard post-contrast T1 weighted sequence would aid SRS 
planning, in terms of increasing the inal planned treatment 
volume or potentially encompassing peritumoral areas 
where local recurrence subsequently occurred.
Materials and methods
Patients
In this retrospective study, 17 consecutive neurosurgical 
patients (median age 54  years, 4 male/13 female) with 
a supratentorial brain metastasis who had undergone 
difusion-weighted MRI (DWI) as part of their preopera-
tive investigations and who had developed recurrence at 
the site of surgery (as per generic RANO criteria [16]) 
were included (Table  1). All patients studied under-
went gross total resection and there were no complica-
tions within 30  days of operation. Median overall sur-
vival was 11.8  months (95% CI 7.8–15.8  months) and 
median time to local recurrence was 8.0 months (95% CI 
6.6–9.4 months).
MRI and analysis
MR imaging was performed on clinical whole body scan-
ners at 1.5T with a single channel head coil. The stand-
ard post-contrast T1-weighted sequence was a volu-
metric fast spoiled gradient echo sequence, which was 
acquired after the intravenous administration of Gada-
vist® (Bayer HealthCare, Germany) at a standard dose 
of 0.1 mmol/kg. The acquisition parameters were as fol-
lows: repetition time (TR) 9 ms, echo time (TE) 1.4 ms, 
lip angle 15 degrees, acquisition matrix 256 × 256, vol-
ume 180 × 1  mm axial slices at zero angulation. DWI 
was obtained using one acquisition over 90  s through 
single-shot echo planar imaging with b values of 0 and 
1000 s/mm2. Using the post processing software package 
GE FuncTool® (v 4.5.5, General Electric Co., Maryland, 
USA), an ADC map was generated for each dataset. All 
patients underwent a control volume CT brain on day 1 
post operatively as per institutional protocol.
Table 1  Demographic and clinical information of the included patients
ID Age (years) Sex Performance 
status (KPS) 
(%)
GPA category Primary cancer Extracranial 
metastases
Status of primary tumour Location of 
brain metas-
tasis
M011 38 F 100 3.0 Melanoma (BRAF+) Present Stable disease Occipital
M013 48 F 90 3.5–4.0 NSCLC Absent Stable disease Frontal
M019 70 F 90 1.5–2.5 Lung NOS Present Synchronous Cerebellar
M028 57 F 70 1.5–2.5 Melanoma Present Synchronous Parietal
M031 70 M 90 3.0 NSCLC Absent Stable disease Occipital
M033 36 F 100 3.5–4.0 NSCLC Absent Synchronous Temporal
M042 60 F 70 1.5–2.5 Unknown Present Synchronous Frontal
M052 48 F 90 3.0 Breast (HER2−) Present Stable disease Parietal
M222 56 F 90 3.5–4.0 NSCLC Absent Stable disease Frontal
M302 35 F 90 3.0 Melanoma (BRAF+) Present Stable disease Parietal
M008 54 F 80 3.0 NSCLC Absent Synchronous Frontal
M257 68 M 90 3.0 NSCLC Absent Synchronous Parietal
M260 67 M 90 3.0 NSCLC Absent Synchronous Occipital
M268 51 M 90 3.5–4.0 NSCLC Absent Stable disease Frontal
M308 56 F 90 3.5–4.0 Breast (HER2+) Absent Stable disease Frontal
M135 27 F 90 3.5–4.0 Breast (HER2−) Absent Stable disease Parietal
M164 53 F 100 1.5–2.5 NSCLC Present Synchronous Frontal
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Stereotactic radiosurgery planning
Scans were transferred to Oncentra MasterPlan® (Nucle-
tron BV, Veenendaal, Netherlands) and target delineation 
performed in a randomized reading order by three separate 
operators experienced in SRS planning and blinded to the 
clinical information and outcome of the patient. Difer-
ent imaging sequences were contoured at diferent days in 
order to avoid pre-imaging bias. Volumetric analysis was 
done within MasterPlan® employing the “Case Explorer” 
tool. We compared treatment volumes based on the post-
contrast T1-weighted scans (GTVT1gad), using the ADC 
maps alone (GTVADC) and using both sequences in com-
bination, which we subsequently refer to as difusion treat-
ment volume (DTV) and then compared these with areas 
of subsequent recurrence after gross total resection. The 
conformity index is a concept in radiation oncology used to 
compare treatment plans and volumes and has a variety of 
derivations and applications. Here an intentionally simple 
approach is used, calculating the ratio of intersection of two 
volumes with their combined total volume to yield an index 
of their conformity from 0, no similarity whatsoever, to 1, 
identical plans (illustrated in Fig. 1).
Results
Clinical outcomes
All patients studied underwent gross total resection 
with no complications within 30  days of operation. 
Median overall survival was 11.8  months (95% CI 7.8–
15.8  months) and median time to local recurrence was 
8.0  months (95% CI 6.6–9.4  months). In ifteen of sev-
enteen cases neurosurgical resection of a solitary cer-
ebral metastasis was followed by adjuvant whole brain 
radiotherapy (WBRT) 30  Gy in 10 fractions. In one 
case the patient was too unwell due to systemic disease 
to receive WBRT and in one other 20 Gy in 5 fractions 
was administered at the treating oncologists’ discretion. 
At recurrence ive patients underwent re-operation, three 
underwent SRS and the remainder received palliative 
chemotherapy.
Assessing treatment volumes
Intra-class correlation coeicient showed strong agree-
ment amongst the three diferent observers; for GTVT1gad 
alpha = 0.998 (95% CI 0.992–0.999) and for GTVADC 
alpha = 0.987 (95% CI 0.958–0.997). Direct pairwise 
comparison of GTVT1gad and GTVADC showed no quan-
titative diference (related samples Wilcoxon signed rank 
test = −0.45, p = 0.653); values are listed in Table  2. 
The conformity index (Fig.  1) was used to qualitatively 
compare the volumes; mean conformity index (±SD) 
for GTVT1gad compared to GTVADC was 0.53 (±0.16), 
which is signiicantly diferent from 1 (one sample t test, 
t = −11.9, df = 16, p < 0.001). As a control, the conform-
ity index for GTVT1gad of diferent observers was calcu-
lated and found to be 0.79 (±0.28) with no signiicant dif-
ference from 1 (p > 0.05).
Fig. 1  Illustration of the conformity index (=intersection vol-
ume ÷ conjunction volume) for comparing treatment volumes based 
on the T1gad and the ADC studies
Table 2  Average metastasis volume as assessed using the standard 
post-contrast planning sequence (T1gad) and the ADC map
Volumes are in cm3
Case ID GTVT1gad GTVADC DTV (union of 
GTVT1gad and 
GTVADC)
M011 18.5 29.81 30.46
M013 10.2 12.57 13.65
M019 38.99 27.88 44.82
M028 12.33 9.4 14.23
M031 49.48 42.35 55.36
M033 16.03 10.07 16.89
M042 71.71 64.51 77.21
M052 4.33 4.27 5.77
M222 7.27 6.8 9.31
M302 14.18 18.58 19.87
M008 2.35 1.5 2.37
M257 4.41 5.48 6.70
M260 0.75 0.49 0.84
M268 4.85 7.56 8.18
M308 9.52 7.05 12.45
M135 8.74 15.06 16.35
M164 1.19 1.74 2.24
Median 9.52 9.40 13.65
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Combining the ADC map with standard planning
The DTV was signiicantly greater than the GTVT1gad 
both quantitatively (related samples Wilcoxon signed 
rank test = 3.621, p < 0.001) and qualitatively (conform-
ity index = 0.74 (±0.17), signiicantly diferent to 1, 
t = −6.27, p = 0.001). There was no signiicant difer-
ence in the volume of recurrent tumour that would have 
been covered by the GTVT1gad vs. the GTVADC (3.53 
and 3.57  cm3 respectively, Wilcoxon related samples 
test = −0.052, p = 0.959) and the conformity index was 
not signiicantly diferent (0.20 ± 0.16 for GTVADC vs. 
0.22 ± 0.20 for GTVT1gad, paired t test = 0.823, p = 0.424). 
The volume of recurrence encompassed by the DTV 
was signiicantly greater than the GTVT1gad in 12 of 16 
individual cases as well as overall for the group (median 
3.84 cc, range 0–32, vs. 3.53 cc, range 0–31), Wilcoxon 
related samples test = −3.061, p = 0.002; this is illustrated 
for one case (M-011) in Fig. 2.
Discussion
We have shown that using an ADC map in addition to a 
conventional post-contrast T1-weighted MRI sequence to 
plan radiosurgery for solitary brain metastases results in 
a greater treatment volume with a diferent conformation 
compared to the standard protocol. Furthermore, this com-
bined treatment volume intersects with a greater volume of 
subsequent local recurrence of that metastasis following 
complete resection. This analysis suggests the ADC map to 
provide additional, diferent, clinically useful information 
compared to the post-contrast T1-weighted sequence alone.
Local recurrence occurs in approximately 20% of cases 
following radiosurgery [17] and poses a clinical problem 
for patients and clinicians. ADC is known to decrease 
with increasing cellularity. Unlike arbitrarily increas-
ing the treated volume, which has not consistently been 
shown to reduce local recurrence [18] and may risk radi-
onecrosis to normal brain [19], using the ADC map to 
plan SRS may therefore cover biologically active areas, 
although it is likely that ADC changes represent a gen-
eralized overall assessment of the underlying biological 
Fig. 2  An occipital metastasis 
in a patient with metastatic 
melanoma (M-011). Treatment 
plans were generated based on 
a the ADC map—GTVADC and 
b the post-contrast T1-weighted 
planning study—GTVT1gad. The 
combined plan with addition 
of these two volumes is termed 
the difusion treatment volume 
or DTV (c). These volumes 
are superimposed on post-
contrast T1-weighted sequences 
acquired at the point when the 
resected tumour recurred. The 
volume of local recurrence that 
was covered by the GTVT1gad 
(d) was less than that covered 
by the DTV (e) and difered in 
conformation
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and pathological processes. ADC changes have been used 
in a radiotherapy planning study to distinguish high-risk 
areas for glioblastoma recurrence [20]; however, to our 
knowledge DWI has never been applied to metastasis 
radiosurgery planning before. The only investigations 
into SRS planning for brain metastases that focussed on 
combining metabolic with anatomic imaging by using 
FDG-PET [21, 22]; this study resulted in modiied treat-
ment plans for 2/3 of brain metastases in a series of 8 
lesions. One further study itted 11-C methionine PET to 
the contrast-enhancing border [23] using a simple model 
to provide metabolic tumour delineation, but did not look 
at outcome parameters.
There are limitations to our study that need to be taken 
into account when interpreting the data. Our study design 
is retrospective in nature, which, however, ofered the 
advantage of a complete follow-up from time of diagnosis 
to death. Further prospective studies could evaluate SRS 
planning based on the ADC map and the post-contrast 
T1-weighted MRI followed by comparison of subsequent 
local recurrence with the original plans. Nevertheless, our 
pilot study conirms that difusion-based plans were of rea-
sonable quality and detail. Moreover, the extent of coverage 
of such plans in regard to surrounding brain tissue and the 
technical integration of difusion-weighted imaging into a 
planning software could be demonstrated. At this point in 
time, ADC may not routinely be added for GTV deinition 
in SRS as normal tissue constraints have to be considered 
and tumour volumes tend to be larger when applying the 
DTV concept as presented. However, if our preliminary 
data are conirmed in future studies, this limitation may 
be overcome by hypo-fractionated stereotactic treatments 
as the risk–beneit ratio will be improved with increasing 
tumour size.
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